Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/133456
Title: | Inhaled amikacin for severe Gram-negative pulmonary infections in the intensive care unit: current status and future prospects |
Author: | Torres Martí, Antoni Motos, Ana Battaglini, Denise Bassi, Gianluigi Li |
Keywords: | Bacteris gramnegatius Unitats de cures intensives Infeccions respiratòries Gram-negative bacteria Intensive care units Respiratory infections |
Issue Date: | 17-Dec-2018 |
Publisher: | BioMed Central |
Abstract: | Recently, the use of nebulized antibiotics in the intensive care unit, in particular amikacin, has been the subject of much discussion, owing to unconvincing results from the latest randomized clinical trials. Here, we examine and reappraise the evidence in favor and against this therapeutic strategy; we then discuss the potential factors that might have played a role in the negative findings of recent clinical trials. Also, we call attention to several factors that are seldom considered by study developers and regulatory agencies, to promote translational research in this field and improve the design of future randomized clinical trials. |
Note: | Reproducció del document publicat a: https://doi.org/10.1186/s13054-018-1958-4 |
It is part of: | Critical Care, 2018, vol. 22, num. 1, p. 343 |
URI: | http://hdl.handle.net/2445/133456 |
Related resource: | https://doi.org/10.1186/s13054-018-1958-4 |
ISSN: | 1364-8535 |
Appears in Collections: | Articles publicats en revistes (Medicina) Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
686795.pdf | 2.7 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License